相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small-cell lung cancer
Zachary A. Yochum et al.
ONCOGENE (2019)
Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer
Shang-Gin Wu et al.
MOLECULAR CANCER (2018)
Wee1 inhibitor MK1775 sensitizes KRAS mutated NSCLC cells to sorafenib
Elisa Caiola et al.
SCIENTIFIC REPORTS (2018)
The relationship between platinum drug resistance and epithelial-mesenchymal transition
Anamaria Brozovic
ARCHIVES OF TOXICOLOGY (2017)
Overcoming resistance to EGFR tyrosine kinase inhibitors in lung cancer, focusing on non-T790M mechanisms
Kenichi Suda et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2017)
Primary Double-Strike Therapy for Cancers to Overcome EGFR Kinase Inhibitor Resistance: Proposal from the Bench
Kenichi Suda et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
A First-in-Class TWIST1 Inhibitor with Activity in Oncogene-Driven Lung Cancer
Zachary A. Yochum et al.
MOLECULAR CANCER RESEARCH (2017)
Functional KRAS mutations and a potential role for PI3K/AKT activation in Wilms tumors
Dina Polosukhina et al.
MOLECULAR ONCOLOGY (2017)
Leptomycin B reduces primary and acquired resistance of gefitinib in lung cancer cells
Zhongwei Liu et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2017)
Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer
Kirstine Jacobsen et al.
NATURE COMMUNICATIONS (2017)
Targeting the miR-200c/LIN28B axis in acquired EGFR-TKI resistance non-small cell lung cancer cells harboring EMT features
Hiroki Sato et al.
SCIENTIFIC REPORTS (2017)
Expression of Neuroendocrine Factor VGF in Lung Cancer Cells Confers Resistance to EGFR Kinase InhibitorsandTriggers Epithelial-to-Mesenchymal Transition
Wen Hwang et al.
CANCER RESEARCH (2017)
FDA Approval of Gefitinib for the Treatment of Patients with Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer
Dickran Kazandjian et al.
CLINICAL CANCER RESEARCH (2016)
Acquisition of anticancer drug resistance is partially associated with cancer sternness in human colon cancer cells
Flaria El Khoury et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2016)
High MET amplification level as a resistance mechanism to osimertinib (AZD9291) in a patient that symptomatically responded to crizotinib treatment post-osimertinib progression
Sai-Hong Ignatius Ou et al.
LUNG CANCER (2016)
Targeting the KRAS Pathway in Non-Small Cell Lung Cancer
Pascale Tomasini et al.
ONCOLOGIST (2016)
Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism
Piro Lito et al.
SCIENCE (2016)
LBA3 * A PHASE I STUDY OF AZD9291 IN PATIENTS WITH EGFR-TKI-RESISTANT ADVANCED NSCLC - UPDATED PROGRESSION FREE SURVIVAL AND DURATION OF RESPONSE DATA
P. A. Janne et al.
ANNALS OF ONCOLOGY (2015)
Role of EGFR mutations in lung cancers: prognosis and tumor chemosensitivity
Kenichi Suda et al.
ARCHIVES OF TOXICOLOGY (2015)
Intratumoral Heterogeneity in EGFR-Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase Inhibition
Margaret Soucheray et al.
CANCER RESEARCH (2015)
Inhibition of Casein Kinase 1 Alpha Prevents Acquired Drug Resistance to Erlotinib in EGFR-Mutant Non-Small Cell Lung Cancer
Alexandra B. Lantermann et al.
CANCER RESEARCH (2015)
Overexpression of CRM1 A Characteristic Feature in a Transformed Phenotype of Lung Carcinogenesis and a Molecular Target for Lung Cancer Adjuvant Therapy
Weimin Gao et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M
Kenneth S. Thress et al.
NATURE MEDICINE (2015)
RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer
Matthew J. Niederst et al.
NATURE COMMUNICATIONS (2015)
A new role for the PI3K/Akt signaling pathway in the epithelial-mesenchymal transition
Wenting Xu et al.
CELL ADHESION & MIGRATION (2015)
Mechanisms of resistance to EGFR tyrosine kinase inhibitors
Lihua Huang et al.
ACTA PHARMACEUTICA SINICA B (2015)
miRNAs and resistance to EGFR-TKIs in EGFR-mutant non-small cell lung cancer: beyond 'traditional mechanisms' of resistance
Biagio Ricciuti et al.
ECANCERMEDICALSCIENCE (2015)
Emodin represses TWIST1-induced epithelial-mesenchymal transitions in head and neck squamous cell carcinoma cells by inhibiting the beta-catenin and Akt pathways
Tzong-Der Way et al.
EUROPEAN JOURNAL OF CANCER (2014)
Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study
Takashi Seto et al.
LANCET ONCOLOGY (2014)
AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer
Darren A. E. Cross et al.
CANCER DISCOVERY (2014)
Dual Inhibition of EGFR with Afatinib and Cetuximab in Kinase Inhibitor-Resistant EGFR-Mutant Lung Cancer with and without T790M Mutations
Yelena Y. Janjigian et al.
CANCER DISCOVERY (2014)
Inhibition of TWIST1 Leads to Activation of Oncogene-Induced Senescence in Oncogene-Driven Non-Small Cell Lung Cancer
Timothy F. Burns et al.
MOLECULAR CANCER RESEARCH (2013)
Transformation to small-cell lung cancer following treatment with EGFR tyrosine kinase inhibitors in a patient with lung adenocarcinoma
Satoshi Watanabe et al.
LUNG CANCER (2013)
The Proto-Oncogene TWIST1 Is Regulated by MicroRNAs
Maarja-Liisa Nairismagi et al.
PLOS ONE (2013)
Twist: a molecular target in cancer therapeutics
Md Asaduzzaman Khan et al.
TUMOR BIOLOGY (2013)
Properties of resistant cells generated from lung cancer cell lines treated with EGFR inhibitors
Gargi Ghosh et al.
BMC CANCER (2012)
EGFR Mutation Heterogeneity and the Mixed Response to EGFR Tyrosine Kinase Inhibitors of Lung Adenocarcinomas
Zhi-Yong Chen et al.
ONCOLOGIST (2012)
TWIST1 a New Determinant of Epithelial to Mesenchymal Transition in EGFR Mutated Lung Adenocarcinoma
Karine Pallier et al.
PLOS ONE (2012)
Chemotherapeutic Sensitization of Leptomycin B Resistant Lung Cancer Cells by Pretreatment with Doxorubicin
Chuanwen Lu et al.
PLOS ONE (2012)
Silencing of Twist1 sensitizes NSCLC cells to cisplatin via AMPK-activated mTOR inhibition
H-O Jin et al.
CELL DEATH & DISEASE (2012)
Akt/PKB-Mediated Phosphorylation of Twist1 Promotes Tumor Metastasis via Mediating Cross-Talk between PI3K/Akt and TGF-β Signaling Axes
Gongda Xue et al.
CANCER DISCOVERY (2012)
HER2 Amplification: A Potential Mechanism of Acquired Resistance to EGFR Inhibition in EGFR-Mutant Lung Cancers That Lack the Second-Site EGFRT790M Mutation
Ken Takezawa et al.
CANCER DISCOVERY (2012)
TWIST and p-Akt immunoexpression in normal oral epithelium, oral dysplasia and in oral squamous cell carcinoma
Brunno-Santos de Freitas Silva et al.
MEDICINA ORAL PATOLOGIA ORAL Y CIRUGIA BUCAL (2012)
p53-dependent anticancer effects of leptomycin B on lung adenocarcinoma
Changxia Shao et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
Quiescent, Slow-Cycling StemCell Populations in Cancer: A Review of the Evidence and Discussion of Significance
Nathan Moore et al.
JOURNAL OF ONCOLOGY (2011)
Combined inhibition of IGFR enhances the effects of gefitinib in H1650: a lung cancer cell line with EGFR mutation and primary resistance to EGFR-TK inhibitors
Yun Jung Choi et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2010)
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
Sreenath V. Sharma et al.
CELL (2010)
Epithelial to mesenchymal transition derived from repeated exposure to gefitinib determines the sensitivity to EGFR inhibitors in A549, a non-small cell lung cancer cell line
Jin Kyung Rho et al.
LUNG CANCER (2009)
Clinical Implications of KRAS Mutations in Lung Cancer Patients Treated with Tyrosine Kinase Inhibitors: An Important Role for Mutations in Minor Clones
Antonio Marchetti et al.
NEOPLASIA (2009)
Induction of EMT by twist proteins as a collateral effect of tumor-promoting inactivation of premature senescence
Stephane Ansieau et al.
CANCER CELL (2008)
Epithelial-mesenchymal transition and the invasive potential of tumors
Nancy Gavert et al.
TRENDS IN MOLECULAR MEDICINE (2008)
KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer
Erminia Massarelli et al.
CLINICAL CANCER RESEARCH (2007)
Molecular context of the EGFR mutations:: Evidence for the activation of mTOR/S6K signaling
E Conde et al.
CLINICAL CANCER RESEARCH (2006)
A twist for survival and cancer progression
A Puisieux et al.
BRITISH JOURNAL OF CANCER (2006)
Establishment of a human non-small cell lung cancer cell line resistant to gefitinib
F Koizumi et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib
EL Kwak et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
分享论文
